NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…
Regulating artificial intelligence doesn’t have to be complicated, some experts say
Artificial intelligence has the potential to revolutionize how drugs are discovered and change how hospitals deliver care to patients. But AI also comes with the